After NASDAQ Debut, Humacyte's Investor Adds $25M Infusion

Humacyte Inc HUMA, which merged with the special purpose acquisition company Alpha Healthcare Acquisition Corp last week, received an immediate capital infusion from Fresenius Medical Care AG & Co FMS.
On Monday, Fresenius announced an additional investment of $25 million after an initial investment of $150 million in 2018.
Fresenius was also the lead investor of private investment in public equity (PIPE), backing Humacyte’s move to merge with the SPAC.
Last week, Humacyte closed the business combination transaction and received approximately $245 million gross proceeds, including a $175 million PIPE financing. The combined company officially began trading on Friday, priced at $10/share.
Humacyte develops its implantable vessels to be non-immunogenic and available “off the shelf” for uses such as vascular access for hemodialysis patients.
Humacyte’s vessel is an investigational product and is currently subject to late-stage clinical trials in the U.S. and Europe.
Price Action: HUMA shares are trading higher by 3.16% at $13.72 on the last check Tuesday.